IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,386 shares of the medical research company’s stock after selling 2,081 shares during the period. Oppenheimer Asset Management Inc.’s holdings in IQVIA were worth $2,407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in IQV. Rise Advisors LLC purchased a new stake in shares of IQVIA in the first quarter worth about $31,000. Versant Capital Management Inc lifted its holdings in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the period. Riverview Trust Co acquired a new stake in shares of IQVIA during the 1st quarter worth approximately $32,000. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA during the 2nd quarter valued at approximately $27,000. Finally, International Assets Investment Management LLC acquired a new position in shares of IQVIA in the 2nd quarter valued at $32,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on IQV shares. Argus raised shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Thursday, September 5th. Evercore ISI raised their price objective on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. increased their target price on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Finally, The Goldman Sachs Group initiated coverage on shares of IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price target for the company. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $266.67.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by company insiders.

IQVIA Trading Up 0.3 %

Shares of IQVIA stock opened at $239.98 on Wednesday. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The stock has a market cap of $43.75 billion, a P/E ratio of 32.78, a P/E/G ratio of 2.24 and a beta of 1.49. The stock’s 50 day simple moving average is $239.12 and its 200-day simple moving average is $234.12.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the business earned $2.22 EPS. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. Analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.